Abstract
Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have